A child dies in an experimental gene-editing trial. Now the industry’s asking questions

A six-year-old girl in China died in March 2025 after participating in an experimental gene-editing trial, prompting renewed concerns across the scientific community regarding safety protocols and ethical oversight in such advanced therapies. The child, who had a non-life-threatening neurodevelopmental disorder, received an experimental brain-directed base-editing therapy that involved infusing millions of viral particles into her spinal fluid. She experienced a severe immune reaction, leading to her death within a week, which an internal ethics board concluded was directly related to the treatment.

The incident, which was reportedly not publicly disclosed by the researchers or institutions involved, came to light through an investigation by *Science* and *Retraction Watch*. Critics highlight that preclinical studies on monkeys had indicated potential risks of organ damage, and the trial's approval preceded a final toxicology report. Furthermore, the girl's parents, who funded a substantial portion of the therapy's development, were allegedly not fully informed of the associated dangers. A paper detailing related preclinical research was later published in *Nature* without any mention of the child's death or the adverse human trial outcome.

This tragic case has intensified the debate surrounding transparency, rigorous ethical reviews, and robust regulatory frameworks for gene-editing treatments, especially for personalized, first-in-human applications involving vulnerable populations like children. The event has also put China's rapidly developing biomedical industry under scrutiny, with Shanghai Jiaotong University School of Medicine initiating an investigation and discussions emerging about the adequacy of existing oversight mechanisms for investigator-initiated trials.